Gennao Bio

📍 Hopewell, United States🗓 Founded 2020👥 28 employees💰 Last funded 2023
Biotechnology🌐 gennao.com
Website LinkedIn
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and systemically deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, including mRNA, synthetic RNA, DNA, si-RNA, ASOs and gene-editing molecules. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Gennao Bio?
Gennao Bio has 1 investors on record on gritt.io, 1 mid-stage.
When did Gennao Bio last raise funding?
The most recent investment in Gennao Bio recorded on gritt.io was in 2023.
When was Gennao Bio founded?
Gennao Bio was founded in 2020.
What industry is Gennao Bio in?
Gennao Bio operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Gennao Bio based?
Gennao Bio is headquartered in Hopewell, United States.